Search Results
May 05, 2026, 11:08 ET Altura Expands Contract with The Michael J. Fox Foundation to Broaden Access to Parkinson's Research Opportunities
www.blaacpd.org), which aims to learn more about gene changes that may cause Parkinson's in Black and African American people."For research to lead to meaningful advances for all, it must represent
More news about: Altura
May 05, 2026, 09:07 ET CapyBio Launches Cell Identity Services to Diagnose Differentiation Failure and Improve Engineered Cells
cell identity, heterogeneity, and regulatory programs within engineered cell populations.CellOracle Differentiation Optimization Analysisuses gene regulatory network modeling and in silico perturbation analysis to prioritize candidate strategies for improving cell identity.CapyBio's platform
More news about: CapyBio
May 05, 2026, 09:00 ET NextGen Jane Discovers Link in Menstrual Fluid Between Estrogen and a Key Marker of Brain Injury
menstrual fluid captures neuro-hormonal dynamics inaccessible through conventional blood draws. Complementary transcriptomic analysis showed that NEFL gene expression varies nearly 13-fold along the inflammatory resolution trajectory of menstruation, further supporting an active neurological signal within
More news about: NextGen Jane
May 05, 2026, 09:00 ET New Mayo Clinic Studies Demonstrate MyPhenome Test Predicts Weight Loss Outcomes Across Treatments, Including GLP-1s and Surgical Interventions
the only test on the market built on prospective, trait-based genetic science.The first study, "Performance of a Machine Learning–Assisted Gene Risk Score for Calories-to-Satiation to Predict Weight Loss After Sleeve Gastrectomy: 10-Year Experience," is the first to find that the MyPhenome
More news about: Phenomix Sciences
May 05, 2026, 08:55 ET Parks Associates Announces 40 Leaders in Connected Living to be Honored at 30th Annual CONNECTIONS™ Conference
President, Alliances & IoT Business Development, Fortune Brands InnovationsKimberly Lancaster, Former Founder, Caster CommunicationsGene LaNois, Vice President, Business Development, VivintStuart Lombard, Founder & CEO, ecobeeJohn Mack, Managing Director & Sector
More news about: Parks Associates
May 05, 2026, 08:30 ET Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deficiency Disorder
encephalopathy caused by alterations in the CDKL5 gene. The condition is characterized by early-onset seizures and significant neurodevelopmental impairment, with a profound impact on affected individuals and their families. Theinvestigational gene therapy program is being developed to target the
More news about: Viralgen
May 05, 2026, 08:30 ET Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deficiency Disorder
encephalopathy caused by alterations in the CDKL5 gene. The condition is characterized by early-onset seizures and significant neurodevelopmental impairment, with a profound impact on affected individuals and their families. Theinvestigational gene therapy program is being developed to target the
More news about: Viralgen
May 05, 2026, 08:30 ET Viralgen s'associe à Elaaj Bio afin de faire progresser le programme de thérapie génique pour le trouble du déficit en CDKL5
clinique »Le trouble du déficit en CDKL5 (CDD) est une encéphalopathie épileptique et du développement rare et grave causée par des altérations du gène CDKL5. Cette maladie se caractérise par des crises d'épilepsie précoces et des troubles neurodéveloppementaux importants, ce qui a un impact profond
More news about: Viralgen
May 05, 2026, 08:30 ET Greenland Mines And Its Subsidiary Major Precious Greenland A/S Join the European Raw Materials Alliance
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds the Skaergaard Project, which hosts a 2022 NI 43-101 Indicated and
More news about: Greenland Mines Ltd
May 05, 2026, 08:00 ET Apertura Gene Therapy and the TSC Alliance Announce Collaboration to Advance Gene Therapy Programs Designed to Treat Tuberous Sclerosis Complex (TSC)
Science.About Apertura Gene TherapyApertura Gene Therapy develops genetic medicines and next-generation AAV capsids that engage human-relevant receptors, aiming to enable more effective and selective gene delivery. The company's lead capsid, TfR1 CapX™, leverages
More news about: Apertura Gene Therapy
May 05, 2026, 07:30 ET PackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026
American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting in Boston, May 11–15, highlighting the company's continued innovation in AAV vector development,
More news about: Packgene
May 05, 2026, 07:00 ET Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
PA-C, and patient ambassador Leah Adams and include a live Q&A for melanoma patients and caregivers. Topics include melanoma basics and the role of gene expression profile (GEP) testing in shared decision-making.
More news about: Castle Biosciences, Inc.
May 05, 2026, 06:00 ET Ecovyst Reports First Quarter 2026 Results and Revises 2026 Outlook
https://investor.ecovyst.com/events-presentations. Investor Contact:Gene Shiels (484) 617-1225 [email protected] About
More news about: Ecovyst Inc.
May 04, 2026, 16:10 ET Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
worldwide. In the U.S., nearly 2,500 people are diagnosed with IDH1-mutant gliomas each year, of which more than 95% harbor a mutation in the IDH1 gene. Most patients are diagnosed in their 30s and 40s. While patients with IDH1 mutations generally have longer survival times than those with wild-type IDH1,
More news about: Nuvation Bio Inc.
May 04, 2026, 16:05 ET Cryoport Reports First Quarter 2026 Financial Results
First quarter revenue grew 16% year-over-year to $47.8 millionCommercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programsLife Sciences Services revenue increased
More news about: Cryoport, Inc.
May 04, 2026, 12:03 ET ProBio De-Risks Cell & Gene Therapy with New Packaging Test
critical need for accelerated decision-making and de-risked progression from discovery to Chemistry, Manufacturing, and Controls (CMC) in cell and gene therapy programs, ProBio Inc. has launched its new Viral Vector Packaging Test. This early-stage development offering provides biopharma
More news about: ProBio Inc
May 04, 2026, 10:30 ET Biologics Safety Testing Market worth $9.66 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144The growth of advanced modalities such as cell & gene therapies and mRNA products is a major driver of the biologics safety testing market. Additionally, the expanding pipeline of biologics and biosimilars,
More news about: MarketsandMarkets
May 04, 2026, 08:30 ET Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies
genome analysis, ChromoSeq enables detection of single‑nucleotide variants, insertions and deletions, copy number alterations, structural variants and gene fusions that are critical for diagnosis, risk stratification and clinical decision‑making.Unlike traditional diagnostic workflows that rely on
More news about: Caris Life Sciences
May 04, 2026, 08:30 ET Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
another company.About McCune-Albright SyndromeMAS is an extremely rare genetic disorder caused by activating mutations in the GNAS gene, leading to mosaic endocrine dysregulation. Because it is so rare and has a broad spectrum of symptoms, diagnosis can be challenging. The disease is
More news about: Atossa Therapeutics Inc
May 04, 2026, 08:09 ET Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting
TegavivintTegavivint is a first-in-class small-molecule inhibitor of TBL1, a critical transcriptional regulator required for nuclear β-catenin stability and oncogenic gene expression. By disrupting the TBL1–β-catenin transcriptional complex, tegavivint promotes degradation of nuclear β-catenin, inhibits oncogenic transcriptional
More news about: Iterion Therapeutics
May 04, 2026, 07:00 ET Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans
Stargardt disease – are examples of genetic disorders that cannot be addressed by standard gene replacement, given the large size of the gene, or by base editing, due to the high mutational variance of the affected gene.About Ascidian TherapeuticsAscidian Therapeutics is redefining the
More news about: Ascidian Therapeutics
May 04, 2026, 07:00 ET Introducing Vylor: Corteva Spinoff to Propel Agriculture Further
germplasm and transformative biotechnology, including a world-class pipeline that includes gamechangers like proprietary hybrid wheat, leadership in gene editing, multi-disease resistance corn and next-generation biofuels. The company will leverage its next generation scientific expertise to further strengthen
More news about: Corteva, Inc.
May 04, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
May 03, 2026, 09:09 ET Everads Announces Publication of First-in-Human Clinical Data for Its Suprachoroidal Injector in Ophthalmology Science and Three Presentations at ARVO 2026
also developing this platform for in-office suprachoroidal buckling to treat select retinal detachments. The company collaborates with partners across gene therapy, cell therapy, small molecule formulations, and other modalities to realize the full potential of its differentiated delivery approach.Founded
More news about: Everads Therapy
May 02, 2026, 15:30 ET BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
This condition is caused by a change in the FGFR3 gene, a negative regulator of bone growth.More than 80% of children with achondroplasia have parents of average stature and have the condition as the result of a spontaneous gene mutation. The worldwide incidence rate of achondroplasia is
More news about: BioMarin Pharmaceutical Inc.